On the relationship between tumour growth rate and survival in non-small cell lung cancer

• Published in: PeerJ (San Francisco, CA) Vol. 5; p. e4111
• Main Author: Mistry, Hitesh B
• Format: Journal Article
• Language: English
• Published: United States PeerJ. Ltd 29.11.2017; PeerJ, Inc; PeerJ Inc
• Subjects: Cancer research; Cancer therapies; Care and treatment; Cell survival; Chemotherapy; Clinical Trials; Decision making; Development and progression; Drug development; Growth models; Growth rate; Longitudinal imaging; Lung cancer; Mathematical Biology; Mathematical models; Medical imaging; Medical prognosis; Medical research; Non-small cell lung cancer; Non-small cell lung carcinoma; Oncology; Patients; Pharmacology; Prognosis; Statistics; Studies; Survival; Tumors; Longitudinal imaging; Survival; Lung cancer
• ISSN: 2167-8359; 2167-8359
• DOI: 10.7717/peerj.4111

A recurrent question within oncology drug development is predicting phase III outcome for a new treatment using early clinical data. One approach to tackle this problem has been to derive metrics from mathematical models that describe tumour size dynamics termed re-growth rate and time to tumour re-growth. They have shown to be strong predictors of overall survival in numerous studies but there is debate about how these metrics are derived and if they are more predictive than empirical end-points. This work explores the issues raised in using model-derived metric as predictors for survival analyses. Re-growth rate and time to tumour re-growth were calculated for three large clinical studies by forward and reverse alignment. The latter involves re-aligning patients to their time of progression. Hence, it accounts for the time taken to estimate re-growth rate and time to tumour re-growth but also assesses if these predictors correlate to survival from the time of progression. I found that neither re-growth rate nor time to tumour re-growth correlated to survival using reverse alignment. This suggests that the dynamics of tumours up until disease progression has no relationship to survival post progression. For prediction of a phase III trial I found the metrics performed no better than empirical end-points. These results highlight that care must be taken when relating dynamics of tumour imaging to survival and that bench-marking new approaches to existing ones is essential.